» Articles » PMID: 38445956

Phytic Acid Maintains Peripheral Neuron Integrity and Enhances Survivability Against Platinum-Induced Degeneration Via Reducing Reactive Oxygen Species and Enhancing Mitochondrial Membrane Potential

Overview
Specialty Neurology
Date 2024 Mar 6
PMID 38445956
Authors
Affiliations
Soon will be listed here.
Abstract

Phytic acid (PA) has been reported to possess anti-inflammatory and antioxidant properties that are critical for neuroprotection in neuronal disorders. This raises the question of whether PA can effectively protect sensory neurons against chemotherapy-induced peripheral neuropathy (CIPN). Peripheral neuropathy is a dose-limiting side effect of chemotherapy treatment often characterized by severe and abnormal pain in hands and feet resulting from peripheral nerve degeneration. Currently, there are no effective treatments available that can prevent or cure peripheral neuropathies other than symptomatic management. Herein, we aim to demonstrate the neuroprotective effects of PA against the neurodegeneration induced by the chemotherapeutics cisplatin (CDDP) and oxaliplatin. Further aims of this study are to provide the proposed mechanism of PA-mediated neuroprotection. The neuronal protection and survivability against CDDP were characterized by axon length measurements and cell body counting of the dorsal root ganglia (DRG) neurons. A cellular phenotype study was conducted microscopically. Intracellular reactive oxygen species (ROS) was estimated by fluorogenic probe dichlorofluorescein. Likewise, mitochondrial membrane potential (MMP) was assessed by fluorescent MitoTracker Orange CMTMRos. Similarly, the mitochondria-localized superoxide anion radical in response to CDDP with and without PA was evaluated. The culture of primary DRG neurons with CDDP reduced axon length and overall neuronal survival. However, cotreatment with PA demonstrated that axons were completely protected and showed increased stability up to the 45-day test duration, which is comparable to samples treated with PA alone and control. Notably, PA treatment scavenged the mitochondria-specific superoxide radicals and overall intracellular ROS that were largely induced by CDDP and simultaneously restored MMP. These results are credited to the underlying neuroprotection of PA in a platinum-treated condition. The results also exhibited that PA had a synergistic anticancer effect with CDDP in ovarian cancer in vitro models. For the first time, PA's potency against CDDP-induced PN is demonstrated systematically. The overall findings of this study suggest the application of PA in CIPN prevention and therapeutic purposes.

Citing Articles

Impact of Vegan and Vegetarian Diets on Neurological Health: A Critical Review.

Clemente-Suarez V, Redondo-Florez L, Martin-Rodriguez A, Curiel-Regueros A, Rubio-Zarapuz A, Tornero-Aguilera J Nutrients. 2025; 17(5).

PMID: 40077754 PMC: 11901473. DOI: 10.3390/nu17050884.

References
1.
Masum Akond A, Crawford H, Berthold J, Talukder Z, Hossain K . Minerals (Zn, Fe, Ca and Mg) and Antinutrient (Phytic Acid) Constituents in Common Bean. Am J Food Technol. 2018; 6(3):235-243. PMC: 5983041. DOI: 10.3923/ajft.2011.235.243. View

2.
Okda T, Katry M, Ragab N, Shalkami A . Phytic acid potentiates oxaliplatin effects in colorectal cancer induced by 1,2-DMH: the role of miR-224 and miR-200a. Contemp Oncol (Pozn). 2021; 25(2):118-124. PMC: 8506431. DOI: 10.5114/wo.2021.106061. View

3.
Lv Y, Zhang Z, Hou L, Zhang L, Zhang J, Wang Y . Phytic acid attenuates inflammatory responses and the levels of NF-κB and p-ERK in MPTP-induced Parkinson's disease model of mice. Neurosci Lett. 2015; 597:132-6. DOI: 10.1016/j.neulet.2015.04.040. View

4.
Waseem M, Parvez S . Neuroprotective activities of curcumin and quercetin with potential relevance to mitochondrial dysfunction induced by oxaliplatin. Protoplasma. 2015; 253(2):417-30. DOI: 10.1007/s00709-015-0821-6. View

5.
Oldenburg J, Fossa S, Nuver J, Heidenreich A, Schmoll H, Bokemeyer C . Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6:vi125-32. DOI: 10.1093/annonc/mdt304. View